Composition for moderating alcohol metabolism and for reducing the risk of alcohol induced diseases

ABSTRACT

The present invention is directed to a composition of matter, in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively. The composition of matter reduces the risk of neuropathy, neurodegenerative diseases including late-onset Alzheimer&#39;s disease, and cancer, in particular of pancreatic, esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breast cancer, in particular the drug and/or alcohol induced risk of said diseases. In this respect, the present invention is also directed to a composition of matter; in particular a food composition, dietary or food supplementation, and pharmaceutical composition, respectively, which supports and/or moderates the alcohol degradation process within the human body.

The present invention is directed to a composition of matter, inparticular a food composition, dietary or food supplementation, andpharmaceutical composition, respectively. The composition of matterreduces the risk of neuropathy, neurodegenerative diseases includinglate-onset Alzheimer's disease, and cancer, in particular of pancreatic,esophageal, oropharyngolaryngeal, liver, colorectal, lung and/or breastcancer, in particular the drug and/or alcohol induced risk of saiddiseases. In this respect, the present invention is also directed to acomposition of matter, in particular a food composition, dietary or foodsupplementation, and pharmaceutical composition, respectively, whichsupports and/or moderates the alcohol degradation process within thehuman body.

The present invention particularly addresses the problem of accumulationof acetaldehyde after rapid alcohol degradation i.e. alcohol metabolismas may occur in most people of Non-Caucasian type genetic structure.

It is assumed that drinking alcoholic beverages is associated with anincreased risk for neuropathy diseases. Ethanol induces a lot of effectson the brain and nerve system which leads to change in behaviour, motorcoordination and, in the extreme case, brain damage. In particular,peripheral nerve polyneuropathy is commonly observed in alcoholicpatients. One possible mediator of the alcohol effects is acetaldehyde,a highly toxic metabolite of ethanol. Acetaldehyde is a highly reactivemolecule with oxidative activity and has cytotoxic effects and modifiesproteins in the cells, leading to their dysfunction.

It is also assumed that drinking alcoholic beverages is associated withan increased risk for neurodegenerative diseases. These diseases areexpected as being caused by the deposition of inclusion bodies in theneuronal cells, and finally disappearance of the cells. Oxidative stressand the following lipid peroxidation caused by oxidants, such asreactive oxygen species, are reported to play an important role in thepathogenesis of neurodegenerative diseases including Alzheimer'sdisease, Parkinson's disease, and cerebral ischemia. Acetaldehyde isthus thought to be the cause of several alcohol-induced neuronalchanges. Acetaldehyde is also suspected to play a pivotal role in thedevelopment of alcohol related cancers because of its established DNAdamaging effects (single-strand and double-strand breaks) andcarcinogenicity in laboratory animals.

It is also assumed that drinking alcoholic beverages is associated withan increased risk for certain kinds of cancer including pancreatic,liver, colorectal, lung, breast, esophageal and oropharyngolarynalcancer. The association of alcohol consumption with increased risk foresophageal and oropharyngolarynal cancer is considered as being evidentat least implicitly from epidemiological studies indicating that alcoholitself and/or its metabolite(s) has carcinogenic potency.

Furthermore, increased estrogen levels in women drinkers appear to be animportant mechanism for development of breast cancer. One possiblemechanism for the increase of estrogen is that overproduced acetic acidafter drinking is converted to steroids. The possible role ofacetaldehyde for the alcohol-induced breast cancer appears to beevident.

A very recent paper (Lancet Oncol 7: 149-156, 2006) discussed therelationship between alcohol consumption and the risk of colorectalcancer and lung cancer.

Ethanol taken into the body is eliminated by its oxidation, mainly inthe liver. Ethanol (CH₃CH₂OH) is first metabolised to acetaldehyde(CH₃CHO) by alcohol dehydrogenase (ADH), and then acetaldehyde (CH₃CHO)is further metabolised to acetic acid (CH₃COOH) by aldehydedehydrogenase (ALDH), mainly by liver aldehyde dehydrogenase 2 (ALDH2).

CH₃CH₂OH+NAD→CH₃CHO+NADH+H⁺

CH₃CHO+NAD+H₂O→CH₃COOH+NADH+H⁺

Most of acetaldehyde generated during alcohol metabolism is promptlyeliminated by ALDH2, the low Km ALDH. There are polymorphic isoforms ofALDH and class 2 ALDH (ALDH2), which has the lowest affinity constant(Km), is the most important enzyme for acetaldehyde oxidation. A mutantallele, ALDH2*2, has a single point mutation (GSA) in exon 12 of theactive ALDH2*1 gene. This mutation results in a substitution of glutamicacid (Glu) at amino acid position 487 by lysine (Lys). ALDH2*2 encodesthus a catalytically inactive subunit and acts in a dominant negativefashion. Individuals with heterozygous ALDH2*1/2*2 genotype should haveonly 6% activity compared to those with normal homozygous ALDH2*1/2*1genotype. Distribution of ALDH2*2 allele varies by race: it is prevalentin East Asia but has not been found in Caucasians and Africans, who havethe active ALDH2*1 allele. 40-50% of East Asians have the inactiveALDH2*2 allele. The average peaks of blood acetaldehyde concentrationsof ALDH2*1/2*2 heterozygotes and ALDH2*2/2*2 homozygotes after drinkingof a small amount of ethanol (0.1 g/kg body weight) are five times and18 times, respectively, of that found in ALDH2*1/2*1 homozygotes afterdrinking of moderate amount of ethanol (0.8 g/kg body weight). Theamount of acetaldehyde in saliva is increased in ALDH2*1/2*2heterozygotes given alcohol, and its level falls when alcohol oxidationof active ALDH2*1/2*1 homozygotes is inhibited by an ALDH inhibitor4-methylpyrazol. Therefore, acetaldehyde oxidation is strikinglyimpaired in individuals with ALDH2*2 allele.

Deficiency of ALDH2 activity is associated with increased the risk ofcancer and therefore acetaldehyde is regarded as a carcinogen. In fact,acetaldehyde can damage culture hepatocytes and results in secondaryhyperproliferation.

It appears also evident that ALDH2 deficiency is associated with anincreased risk of polyneuropathy and of late-onset Alzheimer's disease.Moreover, sensory conduction time is significantly longer in Japanesealcoholic patients with hypoactive ALDH2*2 allele than that in activeALDH2*1/2*1 homozygotes, indicating dysfunction of peripheral neurons ofthe formers. The experimental neuronal cell system, in which ALDH isgenetically inactivated, becomes highly vulnerable to exogenously addedaldehyde metabolite, indicating that oxidative stress caused byacetaldehyde considerably damage neuronal cells. These resultscollectively suggest that oxidative stress induced by acetaldehyde maydamage mitochondrial energy production and modify proteins in theneuronal cells, leading to form the deposition of modified proteins.These changes further damage cellular function and finally cause celldeath. Therefore, acetaldehyde may closely be involved in thepathogenesis of polyneuropathy and/or neurodegenerative diseases such aslate-onset Alzheimer's disease.

It is also assumed that ALDH2 deficiency is associated with an increaseof the risk of breast cancer. Acetaldehyde has a lipophilic nature andaccumulates in adipose tissues. Mammary gland is enriched in fat andother lipophilic tissues. It is concluded that drinking alcoholicbeverages is associated with increases risk for breast cancer. Thepossible role of acetaldehyde for the alcohol-induced breast cancer isthus assumed as well.

For liver cancer it is known that Hepatitis viruses (HV), especially HVBand HVC, increase the risk of liver cancer. However, epidemiologicalsurveys are considered to support that ALDH2 deficiency is alsoassociated with an increased risk of liver cancer for alcohol drinkerswith or without hepatitis viruses. This supports the notion thatacetaldehyde is closely involved in the carcinogenesis of hepatocytes inhuman alcohol drinkers.

Additionally, it appears to be evident that alcoholic beverages arecarcinogenic to humans and causally related to cancer of the oralcavity, pharynx, larynx and esophagus. In particular, it appears thatALDH2 deficiency is also associated with increased the risk of cancer ofthe oral cavity, pharynx, larynx and esophagus. Epithelial cells inthese upper digestive tract are attacked by acetaldehyde not onlydiffused from blood but also secreted from salivary glands afterdrinking, especially in persons with ALDH2*2 allele. The supplement mixaccording to the invention accelerates the disappearance of alcohol andacetaldehyde after drinking in not only ALDH2*1/2*1 homozygotes butALDH2*1/2*2 heterozygotes. The supplement according to the inventioneffectively accelerates alcohol metabolism, and is expected to suppressthe secretion of acetaldehyde from salivary glands. Therefore, thesupplement according to the invention can be used to diminish the riskof cancer of the oral cavity, pharynx, larynx and esophagus.

In Japan, alcoholic pancreatitis is the most common type (68.5%) ofchronic pancreatitis in males. Chronic pancreatitis has been indicatedas a risk factor for pancreatic cancer. While Smoking is awell-documented risk factor for the development of pancreatic cancer, itappears that ALDH2 deficiency increases the risk of pancreatic cancer insmokers and it is assumed that alcohol increases the risk of pancreaticcancer of smokers. These data collectively suggest that alcohol, mostpossibly its metabolite acetaldehyde, takes part in the carcinogenesisof pancreatic cells.

It appears that ALDH2 deficiency is also associated with an increase ofthe risk of pancreatic cancer. Epithelial cells in these upper digestivetract are attacked by acetaldehyde not only diffused from blood but alsosecreted from salivary glands after drinking especially in persons withALDH2*7 allele.

Therefore, it is an object of the present invention to providecompositions effective in reducing alcohol induced diseases.

The object is solved by the subject-matter as defined in the claims.

The following figure is part of the present description and is includedto demonstrate a certain aspect of the present invention. The inventionmay be better understood by reference to this figure in combination withthe detailed description of specific embodiments presented herein.

FIG. 1 shows in a diagram the effects of the composition according tothe present invention on alcohol enhanced metastasis of RPMI4788. ETOHmeans ethanol; SUP means composition according to the present invention;4788 means RPMI4788 cells.

FIG. 2 shows in a diagram the effect of the composition according to thepresent invention on the blood ethanol level. SUP means compositionaccording to the present invention.

FIG. 3 shows in a diagram the effect of the composition according to thepresent invention on the acetaldehyde level. SUP means compositionaccording to the present invention.

FIG. 4 shows in a diagram the effect of the composition according to thepresent invention in comparison to Amino de Kanpai on the blood ethanollevel. SUP means composition according to the present invention.

The term “neuropathy” as used herein, refers to any disease orabnormality of the neurons of the nervous system. “In particular“neuropathy” means a disorder of the peripheral nervous system,affecting nerves anywhere except brain and the spinal cord. Anon-limiting example for neuropathy is alcoholic polyneuropahy which ischaracterized by numbness, abnormal sensations called dysesthesias andallodynias that occur either spontaneously or in reaction to externalstimuli, and a characteristic form of pain, called neuropathic pain orneuralgia.

The term “neurodegenerative disease” as used herein, refers to anydisease or abnormality of the of the nervous system caused bydeterioration of neurons, which include death of neurons and functionalloss of neurotransmitters. Non-limiting examples for a neurodegenerativedisease are Alzheimer's disease and Parkinson's disease.

The term “food composition” as used herein, refers to any kind ofcomposition which is eatable and/or drinkable without causing toxicsymptoms in the subject eating or drinking the respective composition.

The term “supplement”, “dietary supplement” or “food supplement” as usedherein, refers to a composition which is consumed in addition to thedaily meals or in between.

The term “late-onset Alzheimer's Disease” as used herein, refers to theonset of Alzheimer's Disease in elderly people, in particular in peoplebeing 65 years old and older.

The term “flushing syndrome” as used herein, refers to the flushing as aconsequence of drinking alcohol. Flushing is associated with theerythema (reddening caused by dilation of capillaries) of the face,neck, and shoulder, after consumption of alcohol. Flushing after alcoholconsumption is often associated with a range of symptoms: dizziness,nausea, headaches, an increased pulse, occasional extreme drowsiness,and occasional skin swelling and itchiness. There symptoms arecollectively called “Flushing syndrome” or “Asian flush”.

The term “oropharyngolaryngeal cancer” as used herein, refers to cancersderived from oral cavity, pharynx, larynx or upper esophagus. At earlystage of the cancer of this area, the origin could be determined.However, very often, the cancer of this area is found at the lateinvasive stage and the origin cannot be determined. Therefore, cancersarising from this sources are collectively termed “oropharyngolaryngealcancer”.

The term “dosage form” as used herein, refers to an amount of medicationto be taken at one time, optionally in regular intervals.

According to the present invention the object is attained by acomposition of matter comprising the following substances:

-   -   dextrose, Vitamin C, L-glutamine and/or L-glutamic acid,        cysteine, riboflavin, succinic acid, fumaric acid, coenzyme Q10,        and niacin.

The composition according to the present invention reduces the activityor suppresses the production of a particular alcohol dehydrogenaseenzyme, namely the ADH₃, so that the production of acetaldehyde and theethanol metabolism process is slowed down and the alcohol induced peakload on the human organism is reduced. Furthermore, the enzymaticactivity of the aldehyde dehydrogenase ALDH₂ is enhanced, so that themetabolisation of acetaldehyde is supported.

The composition of matter according to the present invention acceleratesthe disappearance of alcohol and acetaldehyde after drinking. Thecomposition is active preferably in ALDH2*1/2*1 homozygote andALDH2*1/2*2 heterozygote subjects. The composition according to thepresent invention effectively accelerates alcohol metabolism andsuppresses the secretion of acetaldehyde from salivary glands.Therefore, the composition according to the present invention can beused to diminish the risk of neuropathy, neurodegenerative diseases,e.g. late-onset Alzheimer's disease, and of cancer, in particular ofpancreatic, esophageal, oropharyngolarynal, colorectal, lung, liver andbreast cancer.

By reducing the peak of excess acetaldehyde entering the blood stream,thereby lowering the risk of damage to vital organs and functions of thehuman body, the composition according to the present invention lowersthe risk of several forms of cancer such as pancreatic, esophageal,oropharyngolarynal, colorectal, lung, liver and/or breast cancer.

By decreasing the concentration of blood acetaldehyde after drinking thecomposition according to the present invention decreases the risk ofpancreatic cancer, preferably for alcohol drinkers with smoking habit,especially those who have the ALDH2*2 allele.

By eliminating acetic acid through activation of the tricarboxylic acid(TCA) cycle and electron transport system, and consequently bypreventing the synthesis of steroids including estrogen the compositionaccording to the invention reduces the risk of breast and liver cancer,preferably for alcohol drinkers, especially those who have the ALDH2*2allele.

The composition of matter according to the present invention containsseveral substances, which are often deficient in patients with alcoholicneuropathy. The composition is thus effective in reducing a flushingsyndrome, reducing the likelihood of headaches and also helps to avoidor ease an alcohol induced hangover the day after. The niacin-fraction(Vitamin B3) included in the composition functions as nicotinamideadenine dinucleotide (AD), which is effective towards a coenzyme toalcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH). Thisvitamin is provided to accelerate ethanol metabolism.

According to a particularly preferred embodiment, the composition alsoincludes pantotheic acid, in particular in the range of about 1 to about5 mg. Pantotheic acid functions as coenzyme A (CoA), which is considerednecessary to metabolize acetic acid. Acetic acid is activated inconjugation with CoA to form acetyl-CoA, which is metabolized in TCAcycle. In enzymatical point of view, elimination of a product (aceticacid) is effective towards an acceleration of the metabolism of asubstrate (acetaldehyde).

Preferably this composition should be taken about 5 minutes prior toconsumption of alcohol and in case of high alcohol consumption againwhilst consuming alcohol. The mass of the composition taken by theconsumer should be in the range of about 70 to 120% of the mass of thealcohol included in the consumed drinks. A standard dose might includeabout 10.0 g dextrose, 1.0 cg Vitamin C, 1.5 g L-glutamine and/orL-Glutamic acid, 500 mg cysteine, 40 mg riboflavin, 100 mg succinicacid, 100 mg fumaric acid, 60 mg coenzyme Q10, and about 10 mg Niacin(Vitamin B3). Preferably the relation of the components of thecomposition is oriented towards the above given relation. The overalldosage may be adapted to the body mass weight of the consumer.

The composition according to the present invention is intended toprevent too much acetaldehyde passing into the mitochondrial matrix andto suppress self blockade of the enzymatic activity of ALDH and thusfacilitate the decomposition of acetaldehyde.

The physiological risks in connection with alcohol consumption maytherefore be significantly reduced by the use of the compositionaccording to the present invention, as this composition facilitates in asynergetic manner an early decrease of the level of acetaldehyde afterdrinking and simultaneously provides a protective effect in respect ofthe suppression of the generation of free radicals.

If the composition is to be administered as a food composition ordietary supplementation it is preferably in such a form, preferably asingredients of a kind of aperitif, that it allows the food compositionto be consumed within a restaurant or a bar prior to consuming alcoholicdrinks. The food composition or dietary supplementation is preferablyconstituted in a manner Wherein a dosage of same is in the form oftablets. Preferably, each tablet is so shaped and dimensioned that itallows said tablet to be easily swallowed. Preferably, said tablets arein such a form that one dosage includes a plurality of those tablets.The tablets may be accommodated within a dosage receptacle whichincludes a number of those tablets. It is possible for the foodcomposition to be in the form of small tablets or balls, and to keepsame in a small tube, while the volume of the food composition taken bythe consumer can be determined with respect to the volume of alcoholwhich is expected to be consumed. The composition or dietarysupplementation may also be in a form similar to sugar-cubes, or mightbe in the form of cryopowder. The composition or dietary supplementationmay be separated into separate subunits. It is possible to provide oneunit, for example a capsule including the Vitamin C fraction, cysteine,riboflavin, succinic acid, fumaric acid and coenzyme Q10, whilst most ofthe dextrose fraction is kept in separate units, capsules, tablets orthe like. It is possible to add further substances such as fruit juiceextracts, curcuma, tannin, a powder of Panax notoginseng, and Vincarosea in suitable amounts. Oolong tea, aloe vera and spiral water algaemight also be added. The composition or dietary supplementation may alsobe in the form of a liquid, in particular a sirup-type liquid. It ispossible to provide the food composition in the appearance of a softdrink in a small bottle.

Preferably a dosage for a person with a body weight of about 80 kgincludes a dextrose fraction of approx. 75%. Such a dosage is to providea considerable moderation in degrading about 18 ml alcohol.

The composition is preferably constituted in a manner wherein a dosageof same, includes a dextrose fraction of about 75.2 mass %, i.e. aquantity of dextrose in the range from 7.2 to 12.8 g, preferably 10.0 gwithin a dose of 13.3 g.

The composition is preferably constituted in a manner wherein a dosageof same includes a Vitamin C fraction of about 7.5 mass % i.e. aquantity of Vitamin C in the range from 0.78 to 1.18 g, preferably 1.0g, within a dose of 13.3 g. The composition is preferably constituted ina manner wherein a dosage of same includes a L-glutamine and/orL-glutamic acid fraction of about 11.27 mass %, i.e. a quantity of saidL-glutamine and/or L-glutamic acid fraction in the range from 1.23 to1.7 g, preferably 1.5 g, within a dose of 13.3 g.

The composition is preferably constituted in a manner wherein a dosageof same includes a cysteine fraction of about 3.76 mass %, i.e. aquantity of said cysteine fraction in the range from 460 to 540 mg,preferably 500 mg, within a dose of 13.3 g.

The composition is preferably constituted in a manner wherein a dosageof same includes a riboflavin fraction of about 0.30 mass % i.e. aquantity of said riboflavin in the range from 32 to 48 mg, preferably 40mg, within a dose of 13.3 g.

The composition is preferably constituted in a manner wherein a dosageof same includes a succinic acid fraction of about 0.752 mass %, i.e. aquantity of said succinic acid in the range from 90 to 110 mg,preferably 100 mg, within a dose of 133 g.

The composition is preferably constituted in a manner wherein a dosageof same includes a fumaric acid fraction of about 0.752 mass %, i.e. aquantity of said fumaric acid in the range from 90 to 110 mg, preferably100 mg, within a dose of 13.3 g.

The composition is preferably constituted in a manner wherein a dosageof same includes a coenzyme Q10 fraction of about 0.451 mass %, i.e. aquantity of said coenzyme fraction in the range from 50 to 70 mg,preferably 60 mg, within a dose of 13.3 g.

The composition is preferably constituted in a manner wherein a dosageof same includes a niacin fraction of about 1 to 20 mg, preferably 15 mgwithin a dose of 13.3 g.

More preferably each ingredient of the composition other than niacin isin the range from about 0.01 to about 100 gram, preferably from about0.05-50 gram, wherein niacin is in the range from about 1 to 20 mg.

The composition is considered to provide the following achievements:

-   -   1. Reduction of ethanol metabolism by slowing down the process        of ethanol oxidation into acetaldehyde, to prevent accumulation        of acetaldehyde in the first place.    -   2. Stimulation of the activity of ALDH and avoiding any blockade        of its enzymatic activity.    -   3. Speeding up the reaction from acetaldehyde to acetic acid and        the further decomposition in the citrate cycle.    -   4. Improving the levels of those anti-oxidants of the alcohol        consumer, which specially protect against toxic effects of        acetaldehyde.

The first achievement is believed to be reached by the intake of a largedose of dextrose sugar (glucose).

Glucose is rapidly oxidised in the cytosol of liver cells using, thesame cytosol NAD pool used by ethanol to be converted into acetaldehyde.Because the amount of cytosolic NAD is limited and can only constantlybe reproduced from NADH+H⁺ much less acetaldehyde accumulates.

The second achievement is also believed to be achieved by the intake ofa large dose of glucose. Glucose augments the enzymatic activity of ADHas well as of ALDH. When a large glucose load occurs in the cytosol ofliver cells then there is no possibility that the acetaldehyde reacheslevels which could lead to inactivation of ALDH or to mitochondrialdestruction.

The third achievement is believed to be performed by

-   -   a) Accelerating the reoxidation from NADH+H⁺ to NAD by speeding        up the transport of electrons through the inner mitochondrial        membrane    -   b) Accelerating the Krebs cycle It is believed to be achieved by        the inclusion of coenzyme Q₁₀ and riboflavin.

Riboflavin will quickly be transformed to FMN, which together withcoenzyme Q₁₀ is the determining substance for the speed of thereoxidation of NADH+H₊ to NAD₊ in the mitochondrial matrix. Acetaldehydeneeds NAD+ when it is metabolised to acetic acid. Within this reactionNAD is transformed into NADH+H⁺. Because the availability of NAD islimited in the mitochondrial matrix NADH+H⁺ has to be re-transformedinto NAD to serve again for acetaldehyde decomposition. This reaction isonly possible because FMN and coenzyme Q₁₀ absorb the electrons ofNADH+H⁺ and shuttle them through the mitochondrial membrane. The moreFMN and coenzyme Q₁₀ are available, the more this process is speeded upand, because more NAD is available, the metabolism of acetaldehyde isaccelerated.

It is known that the inclusion of coenzyme Q₁₀ decreases in the humanbody with progressing age.

The activation of the Krebs (citrate) cycle is achieved by the inclusionof succinic acid and fumaric acid. Both substances activate the secondhalf of the citrate cycle and thereby activate the aerobic oxidationprocess in mitochondria. L-glutamic acid is quickly covert toL-glutamine after absorption in human body, and L-glutamine helps tospeed up the mitochondria-cytosolic malate/asparate shuttle, which playsa key role in the course of intoxication by acetaldehyde. It also speedsup the succinate oxidation process by preventing oxalic and aceticinhibition of succinate dehydrogenase.

The fourth achievement, the elevation of anti-oxidant levels, isachieved by the inclusion of cysteine, ascorbic acid and also ofL-glutamine and/or L-glutamic acid. Cysteine should provide a stronganti-oxidant effect as well as ascorbic acid. The human body transformscysteine to gluthatione which specially protects against the toxiceffects of acetaldehyde. To reach an optimal level of gluthatione and toavoid cysteine being transformed to cystine, it is important to combinecysteine with glutamine and give twice as much ascorbic acid ascysteine.

By administering the mentioned substances, the level of acetaldehydeafter drinking alcohol will be remarkably reduced and flushing symptomsat least diminished. The other known side-effects of acetaldehyde suchas headaches and hangovers should also disappear.

Thus, the present invention relates to a composition for reducingalcohol induced risk of neuropathy, neurodegenerative diseases includinglate-onset Alzheimer's disease and of cancer, in particular ofesophageal, oropharyngolarynal, colorectal, lung, liver, breast and/orpancreatic cancer by moderating an alcohol degradation process inrespect to ethanol metabolism within the human body. The composition ofthe present invention includes the following substances inphysiologically relevant amount: niacin (Vitamin B3), dextrose, VitaminC, L-glutamine and/or L-glutamic acid, cysteine, riboflavin, succinicacid, fumaric acid, and coenzyme Q10.

Furthermore, the compositions according to the present invention can beused as a pharmaceutical. The pharmaceutical or medicament,respectively, can be used for example for the manufacture of amedicament for the treatment and/or prophylaxis of cancer. By way ofnon-limiting example, such cancers can be selected from breast cancer,liver cancer, pancreatic cancer, esophageal cancer, colorectal cancer,lung cancer and oropharyngolaryngeal cancer.

In a further embodiment the composition of the present invention canalso be used for the manufacture of a medicament for the prevention oftumour metastasis in general.

In a further embodiment, the composition of the present invention canalso be used for the manufacture of a medicament for the treatmentand/or prophylaxis of neuropathy and treatment and/or prophylaxis of aneurodegenerative disease, in particular of late-onset Alzheimer'sDisease.

In a further embodiment the composition according to the presentinvention can also be used for the manufacture of a medicament for thetreatment and/or prophylaxis of hangover, flushing syndrome, headacheand/or alcoholic intoxication.

In a further embodiment the composition according to the presentinvention is present in the form of tablets. In a further embodiment adose of the composition according to the present invention includes aplurality of small tablets or capsules. In particular said tablets orcapsules can be contained in a dosage receptacle. In another embodimentthe composition according to the present invention is of a sugar-cubetype form. In another embodiment the composition according to thepresent invention is in the form of cryopowder. In another embodimentthe composition according to the present invention is in the form of asmall drink unit. In another embodiment the composition according to thepresent invention is in the form of a sirup.

In a further aspect the present invention relates to a composition, foodor dietary supplementation, and pharmaceutical composition for reducingalcohol induced risk of neuropathy and/or neurodegenerative diseasesincluding late-onset Alzheimer's disease, esophageal cancer,oropharyngolarynal cancer, breast cancer, liver cancer, lung cancer,colorectal cancer and/or pancreatic cancer, said composition includingniacin for affecting an alcohol degrading process in particular inrespect to ethanol metabolism within the human body, and substances, inparticular substances mentioned above, providing the following effectswithin the human body: —Reducing ethanol metabolism by slowing down theprocess of ethanol oxidation into acetaldehyde, to prevent accumulationof acetaldehyde in the first place; —Stimulating the activity of ALDHand avoiding any blockade of its enzymatic activity; —Speeding up thereaction from acetaldehyde to acetic acid and further decomposition inthe citrate cycle; —Improving the levels of those anti-oxidants of thealcohol consumer which specially protect against toxic effects ofacetaldehyde.

As mentioned above, the present invention relates to a compositioncomprising niacin (Vitamin B3), dextrose, Vitamin C, L-glutamine and/orL-glutamic acid, cysteine, riboflavin, succinic acid, fumaric acid andcoenzyme Q10. As mentioned above there are various embodiments of thiscomposition.

EXAMPLES Example 1 Supplement Solution and Animals

Ingredients of Supplement except Coenzyme Q10 were purchased from SigmaAldrich Japan (Tokyo, Japan). Ten gram of dextrose, 1.0 gram of VitaminC, 1.5 gram of L-glutamine, 500 mg of cysteine, 40 mg of riboflavin, 100mg of succinic acid, 100 mg of fumaric acid, and 10 mg of niacin weredissolved in 100 ml of distilled water (Supplement Solution). Onehundred mg of Coenzyme Q10 (Jarrow Formulas, Los Angels, Calif., USA)was dissolved in 14 ml of sesame oil.

Male, 6-week-old nude mice of BALB/cA-jcl-nu/nu class were purchased(Clea Japan Inc., Shizuoka, Japan) and allowed to acclimate for one weekprior to the study. During the experiment the mice were maintained at atemperature of 23° C., 50% humidity and a specific-pathogen-free (SPF)condition.

Example 2 Cell Line and Metastatic Experiments

RPMI4788 cells derived from human colorectal cancer generate pulmonarymetastasis in nude mouse (Moore G E & Koike A (1964), Cancer January,17: 11-20; Kondo H. et al. (1987), Jpn J Cancer Res (Gann) 78, 12:1400-1408). The cell line was subcultured in tissue culture flasks withculture medium of RPMI1640 solution (Nikken Biomedical Laboratory,Kyoto, Japan) supplemented with 10% Fetal Bovine Serum (FBS) (HycloneLaboratories Inc., Logan, Utah) at 37° C., in an atmosphere of 100%humidity, 5% CO, and 95% air. Following isolation of the cultured cellsby 0.02% EDTA, a cell suspension vas prepared using PBS of 0.01M; trypanblue staining confirmed cell viability over 98%.

To produce lung metastases, nude mice were injected cell suspension of5×10⁴/0.1 ml into tail vein. Twenty-eight days after the injection, allmetastatic nodules on the lung surface were counted. The lung was fixedin 10% neutral formaldehyde and embedded in paraffin. Sections werestained with Hematoxylin-Eosin and examined histologically.

For testing the supplement, 320 μl of supplement solution and 50 μl ofCo-Q10 dissolved sesame oil per mouse were administrated to the stomachby oral metal tube. For assaying the effects of Supplement+EtOH, onehour after the supplement administration, 7.0 ml/kg of ethanol wereinjected into the peritoneal cavity. Then 1 hour after the ethanolinjection, 5×10⁴/100 μl of RPMI4788 cells were injected into the tailvein. The nude mice were sacrificed 28 days after the cell injection andthe metastatic nodules on the lung surface were counted.

The results of these experiments are shown below in table 1.

TABLE 1 Number of Metastatic nodules on the lung surface 4788 ETOH +SUP + SUP + Exp. (Control) 4788 4788 ETOH ++ 4788 14 48 28 49 27 70 2446 31 64 54 80 61 68 28 66 41 75 40 46 82 58 34 21 37 69 45 64 9 62 6779 16 18 21 9 14 19 13 11 14 21 15 12 12 24 13 14 16 19 11 16 16 20 1714 17 21 16 15 18 20 17 14 Total 425 676 443 556 Average 26.6 42.25 27.734.75 minus 4788 0 251 18 131 52.20%

Two independent experiments with eight mice each were performed. Averagemetastatic nodules on lung surface in the Control (only 4788 cells):26.6, Ethanol+4788 cells: 42.25, Supplement+4788 cells: 27.7,Supplement+Ethanol+4788 cells: 34.75. These results show that thesupplement according to the invention did not effect the metastaticpotential of 4788 cell line. Ethanol enhanced approximately 60% ofmetastatic potential of 4788 cell line. Supplement reduced half ofmetastasis which enhanced by ethanol. Difference between the group ofEthanol+4788 cells and Supplement+Ethanol+4788 cells are significantly(P=0.03) by t-test.

Example 3 NK-Activity

A short-term ⁵¹Cr-release assay was used to determine the natural killer(NK) cytotoxic activity. Mice were divided in following 3 groups;control, ethanol administration, and Supplement and ethanoladministration. Twenty four hours after the ethanol administration,splenocytes of the nude mouse were separated as single cell suspension.Target YAC-1 cells (1×10⁷) were labeled by incubation with 200 μCi of⁵¹Cr for 2 hours at 37° C. After being washed and then incubated for 2hours at 37° C., the cells were supplemented in RPMI1640 medium 20 μl ofthe labeled target cells and 100 μl of effector cells were mixed into a96-well microtiter plate (Sumitomo Bakelite Co., Ltd., Tokyo, Japan) atvarious effector/target cell ratios. After 4 hours of incubation, theplates were centrifuged and the radioactivity of the supernatant wasmeasured by a gamma-counter. The percent of cytotoxicity was calculatedas (experimental group release—spontaneous release/totalrelease—spontaneous release). Statistical analysis of the results wasconducted by t² test, and p<0.5 was defined as the level ofsignificance. The results of this experiments are shown in the table 2below.

TABLE 2 Sponta- neous Total ⁵¹Cr ⁵¹Cr Con- Supple. + release releasetrol EtOH EtOH Average cont 264.3 2966.3 930.6 568.6 771.8 NK activity24.60% 11.20% 18.70% % Control 45.5% % increase 55.9 NK

Thus, Ethanol reduced NK activity of control nude mice to 45.5%, andthis effect induced by acetaldehyde as previously reported in manymanuscripts. Supplement increased 55.9% NK activity which reduced byEthanol. Supplement may reduce the acetaldehyde in nude mice like humanand NK activity.

Example 4 Supplement Preparation, Human Volunteers and Alcohol

Ingredients of Supplement except Coenzyme Q10 were purchased from SigmaAldrich Japan (Tokyo, Japan). AQUAQ10P40 (Nissin Pharma. Tokyo Japan)which is powder form and contains 40% of Coenzyme Q10 was used asCoenzyme Q10. One gram of Vitamin C, 1.5 gram of L-glutamic acid, 500 mgof cysteine, 40 mg of riboflavin, 100 mg of succinic acid, 100 mg offumaric acid, 10 mg of niacin and 250 mg of AQUAQ10P40 (exact volume as100 mg of Coenzyme Q10) were mixed. Supplement mixture was dissolved 100ml water just before drink.

Four healthy adults volunteers (two mail and two female, age 26-48) wereagreed with alcohol consumption and blood sampling. Four hundred ml ofred wine which contains 12.5% of ethanol was used as alcohol, and thisamount is exactly same as 50 gram of ethanol. Red wine was administeredduring the first interval of 30 minute from the start of experiments.Control and supplement study was examined different date.

Example 5 Blood Sampling, and the Measurement of Blood Ethanol andAcetaldehyde

Blood sample was taken at the following 4 times: before the alcoholadministration (0), and 30, 60, and 90 minutes after alcoholadministration (30, 60, 90 min). Supplement was orally taken with 100 mlwater 20 minutes before the administration. For the ethanol measurement,whole blood was stored at 4° C. in heparin coated tube. For theacetaldehyde measurement, blood samples were immediately centrifuged byheparin coated tube at 1500 rpm×10 minutes, and serum were frozen at−80° C. Ethanol and acetaldehyde were measured by bio medicallaboratories company BML, INC. (Shibyya-ku, Tokyo, Japan). Statisticalanalysis of the results was conducted by t² test, and p<0.5 was definedas the level of significance. The results of this blood ethanolexperiments are shown in the table 3 below.

TABLE 3 The effects of supplement on human blood ethanol Time 0 30 min60 min 90 min without SUP 0 83.75 80.75 70.25 with SUP 0 24.75 50.75 45(Data indicated are average of 4 sample. mg/dl)

The supplement (composition of the present invention) reduced the bloodethanol level in comparison to the control at the time points 30, 60 and90 minutes after administration of the alcohol. Significant difference(P<0.05) was observed between control and supplement study at the time60 and 90 minutes.

The results of this blood acetaldehyde experiments are shown in thetable 4 below.

TABLE 4 The effects of supplement on human blood acetaldehyde Time 0 30min 60 min 90 min without SUP 0 2.125 1.65 1.7 with SUP 0 0.575 0.4750.475 (Data indicated are average of 4 sample. μM)

The supplement (composition of the present invention) keeps low bloodacetaldehyde level in comparison to the control at the time points 30,60 and 90 minutes after administration of the alcohol. Significantdifference (P<0.05) was observed between control and supplement study atthe time 30, 60 and 90 minutes.

Example 6 Comparison of Composition of the Present Invention and AminoDe Kanpai

Amino de Kanpai is a product of Ajinomoto (Tokyo, Japan) which is soldin Japanese market since March 2006, and contains 1.4 gram of Glutamineand 1.4 gram of Alanine. Ajinomoto markets Amino de Kanpai as an alcoholreducing compositions for human subjects. Furthermore, the compositionsshould reduce headache and discomfort caused by alcohol. In thisexperiments, all conditions of the experiment is identical to theconditions of Example 4 and 5 above except that 3 volunteersparticipated and one portion of Amino de Kanpai (3.0 gram) wasadministered 20 minutes before the administration of alcohol. Theresults of blood ethanol levels with Amino de Kanpai, and correspondentdata of control and supplements (SUP: composition of the presentinvention) are shown in the table 5 below.

TABLE 5 Comparison of composition of the present invention and Amino deKanpai Time 0 30 min 60 min 90 min Control 0 57.6 79 70 with Amino deKanpai 0 58.3 71 61 with SUP 0 26 54.3 48.3 (Data indicated are averageof 3 sample. mg/dl)

Amino de Kanpai showed slight effects of ethanol reduction compare tothe control. Reduction ratio of ethanol at the 90 minutes was 12.8% forAmino de Kanpai, and 31% for SUP. There was no significant differencebetween Amino de Kanpai and control by t² test.

1. A composition comprising niacin, dextrose, Vitamin C, L-glutamineand/or L-glutamic acid, cysteine, riboflavin, succinic acid, fumaricacid and coenzyme Q10.
 2. The composition according to claim 1, whereinthe composition further comprises pantotheic acid.
 3. The compositionaccording to claim 1, wherein the composition comprises a dextrosefraction of about 75.2 mass %.
 4. The composition according to claim 1,wherein the composition comprises a Vitamin C fraction of about 7.5 mass%.
 5. The composition according to claim 1, wherein the compositioncomprise an L-glutamine and/or L-glutamic acid fraction of about 11.28mass %.
 6. The composition according to claim 1, wherein the compositioncomprises a riboflavin fraction of about 3.76%.
 7. The compositionaccording to claim 1, wherein the composition comprises a riboflavinfraction of about 0.3%.
 8. The composition according to claim 1, whereinthe composition comprises a succinic acid fraction of about 0.752 mass%.
 9. The composition according to claim 1, wherein the compositioncomprises a fumaric acid fraction of about 0.752%.
 10. The compositionaccording to claim 1, wherein the composition comprises a coenzyme Q10fraction of about 0.451 mass %.
 11. The composition according to claim1, formulated as pharmaceutical composition.
 12. A method of treating adisease or disorder selected from the group consisting of cancer, tumormetastasis, neuropathy, neurodegenerative disease, hangover syndrome,flushing syndrome, headache and/or alcoholic intoxication comprisingadministering to a subject suffering from one of the foregoing diseasesor conditions a composition comprising niacin, dextrose, Vitamin C,L-glutamine and/or L-glutamic acid, cysteine, riboflavin, succinic acid,fumaric acid and coenzyme Q10.
 13. The method according to claim 12,wherein the cancer is selected from the group consisting of breastcancer, liver cancer, colorectal cancer, lung cancer, pancreatic cancer,esophageal cancer and oropharyngolaryngeal cancer.
 14. The methodaccording to claim 12, wherein the neurodegenerative disease isAlzheimer's Disease, in particular late-onset Alzheimer's Disease. 15.The composition of claim 1, wherein the composition is present in dosageform, as cryopowder, as liquid, in particular as small drink unit or assirup.
 16. The composition according to claim 15, wherein the dosageform is in particular in form of tablets or in sugar-cube type form orwherein a dose comprises a plurality of small tablets or capsules. 17.The composition according to claim 16, wherein the tablets or capsulesare present in a dosage receptacle.